Skip to main content

REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers

17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS” service. REPROCELL will start taking orders from January 2021 in Japan. REPROCELL has also launched a new B2C website to promote the Personal iPS service, which is currently only available in Japan.


Create a new (potential) medical treatment for your children

Visit our Personal iPS website and discover how induced pluripotent stem cells (iPSCs) can be generated from your child's unneeded teeth or urine and stored for future medical use.

 Personal iPS

Personal iPS is a service that prepares and stores an individual’s iPSCs for the regenerative treatment of future illness or injury. Individual’s iPSCs are created from mature cells contained in their urine or dental pulp, using state-of-the-art RNA reprogramming technology. The iPSCs are then stored at two locations in Japan and the United States to establish back-up in case of storage interruption in either facility

“We are incredibly excited to announce this new regenerative medicine initiative,” said Chikafumi Yokoyama, REPROCELL CEO. “We hope that Personal iPS will offer better health outcomes and quality of life for patients.”

Specific advantages of Personal iPS compared with other providers include:

  • Painless collection of tissue for the creation of iPSCs
  • Risk of transplant rejection is negated, as the patients own tissues are used
  • iPSCs are stored at two sites in different countries in case of natural disasters
  • Foot-print-free mRNA technology is used, creating the highest-quality iPSCs

Stem cells are naïve cells which have the power to be transformed into any tissue, including those which make up the nervous and cardiovascular systems. Induced pluripotent stem cells (iPSC) are a type of stem cell which can be made from a person’s mature cells, rather than unborn embryos. Since these cells are obtained from the individual themselves, and not another tissue donor, the risk of transplant rejection can be avoided.

Several diseases are currently treated using stem cells, and clinical trials are underway for the use of iPSCs similar manner. By storing these cells in advance, REPROCELL can reduce the time taken to prepare and deliver regenerative medicine treatments. For further information please visit the  Personal iPS website.

About REPROCELL: REPROCELL Inc. was established in 2003 to contribute to people's health and welfare through the development of stem cell technologies. It was the first stem cell company in Japan. Today the company has evolved and become more international through global acquisitions. The corporate mission is defined as "improving human health through biomedical innovation and discovery".

Subscribe to receive updates from REPROCELL